1
|
Beretta M, Pinto JT, Laggner P, Paudel A. Insights into the Impact of Nanostructural Properties on Powder Tribocharging: The Case of Milled Salbutamol Sulfate. Mol Pharm 2022; 19:547-557. [PMID: 35044180 DOI: 10.1021/acs.molpharmaceut.1c00668] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The impact of the crystallinity of organic solid materials on their tribocharging propensity is well reported. However, no unequivocal explanation about the potential underlying mechanism(s) could be found so far in the literature. This study reports the effect that different degrees of crystalline disorder has on the tribocharging propensity of a small molecular organic material, salbutamol sulfate (SS). Ball-milling was used to induce structural transformations in the crystalline structure of SS. Particles with different nanostructures were produced and analyzed for their solid-state, particle properties, and tribocharging. It was found that differences in the amorphous content among the processed particles and related moisture levels had an impact on powder tribocharging. A correlation between the latter and the nanostructural properties of the particles was also established. The presence of interfaces between nanodomains of different densities and shorter average lengths within the phases seems to lead to a mitigation of charge. This suggests that undetected, subtle nanostructural differences of materials can affect powder handling and processability by altering their tribocharging. The present findings demonstrate the nanostructural implications of powder triboelectrification, which can help toward the rational design of a wide variety of organic solids.
Collapse
Affiliation(s)
- Michela Beretta
- Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13/II, Graz 8010, Austria.,Institute of Process and Particle Engineering, Graz University of Technology, Graz 8010, Austria
| | - Joana T Pinto
- Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13/II, Graz 8010, Austria
| | - Peter Laggner
- Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13/II, Graz 8010, Austria
| | - Amrit Paudel
- Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13/II, Graz 8010, Austria.,Institute of Process and Particle Engineering, Graz University of Technology, Graz 8010, Austria
| |
Collapse
|
2
|
Phan-Xuan T, Bogdanova E, Millqvist Fureby A, Fransson J, Terry AE, Kocherbitov V. Hydration-Induced Structural Changes in the Solid State of Protein: A SAXS/WAXS Study on Lysozyme. Mol Pharm 2020; 17:3246-3258. [PMID: 32787275 PMCID: PMC7482395 DOI: 10.1021/acs.molpharmaceut.0c00351] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
![]()
The stability of biologically produced
pharmaceuticals is the limiting
factor to various applications, which can be improved by formulation
in solid-state forms, mostly via lyophilization. Knowledge about the
protein structure at the molecular level in the solid state and its
transition upon rehydration is however scarce, and yet it most likely
affects the physical and chemical stability of the biological drug.
In this work, synchrotron small- and wide-angle X-ray scattering (SWAXS)
are used to characterize the structure of a model protein, lysozyme,
in the solid state and its structural transition upon rehydration
to the liquid state. The results show that the protein undergoes distortion
upon drying to adopt structures that can continuously fill the space
to remove the protein–air interface that may be formed upon
dehydration. Above a hydration threshold of 35 wt %, the native structure
of the protein is recovered. The evolution of SWAXS peaks as a function
of water content in a broad range of concentrations is discussed in
relation to the structural changes in the protein. The findings presented
here can be used for the design and optimization of solid-state formulations
of proteins with improved stability.
Collapse
Affiliation(s)
- Tuan Phan-Xuan
- Biomedical Science, Malmö University, 214 32 Malmö, Sweden.,Biofilms Research Center for Biointerfaces, Malmö University, 214 32 Malmö, Sweden.,Max IV Laboratory, Lund University, 224 84 Lund, Sweden
| | - Ekaterina Bogdanova
- Biomedical Science, Malmö University, 214 32 Malmö, Sweden.,Biofilms Research Center for Biointerfaces, Malmö University, 214 32 Malmö, Sweden
| | | | | | - Ann E Terry
- Max IV Laboratory, Lund University, 224 84 Lund, Sweden
| | - Vitaly Kocherbitov
- Biomedical Science, Malmö University, 214 32 Malmö, Sweden.,Biofilms Research Center for Biointerfaces, Malmö University, 214 32 Malmö, Sweden
| |
Collapse
|
3
|
Petroková H, Mašek J, Kuchař M, Vítečková Wünschová A, Štikarová J, Bartheldyová E, Kulich P, Hubatka F, Kotouček J, Turánek Knotigová P, Vohlídalová E, Héžová R, Mašková E, Macaulay S, Dyr JE, Raška M, Mikulík R, Malý P, Turánek J. Targeting Human Thrombus by Liposomes Modified with Anti-Fibrin Protein Binders. Pharmaceutics 2019; 11:pharmaceutics11120642. [PMID: 31810280 PMCID: PMC6955937 DOI: 10.3390/pharmaceutics11120642] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 11/20/2019] [Accepted: 11/26/2019] [Indexed: 12/22/2022] Open
Abstract
Development of tools for direct thrombus imaging represents a key step for diagnosis and treatment of stroke. Nanoliposomal carriers of contrast agents and thrombolytics can be functionalized to target blood thrombi by small protein binders with selectivity for fibrin domains uniquely formed on insoluble fibrin. We employed a highly complex combinatorial library derived from scaffold of 46 amino acid albumin-binding domain (ABD) of streptococcal protein G, and ribosome display, to identify variants recognizing fibrin cloth in human thrombus. We constructed a recombinant target as a stretch of three identical fibrin fragments of 16 amino acid peptide of the Bβ chain fused to TolA protein. Ribosome display selection followed by large-scale Enzyme-Linked ImmunoSorbent Assay (ELISA) screening provided four protein variants preferentially binding to insoluble form of human fibrin. The most specific binder variant D7 was further modified by C-terminal FLAG/His-Tag or double His-tag for the attachment onto the surface of nanoliposomes via metallochelating bond. D7-His-nanoliposomes were tested using in vitro flow model of coronary artery and their binding to fibrin fibers was demonstrated by confocal and electron microscopy. Thus, we present here the concept of fibrin-targeted binders as a platform for functionalization of nanoliposomes in the development of advanced imaging tools and future theranostics.
Collapse
Affiliation(s)
- Hana Petroková
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v.v.i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic; (H.P.); (M.K.)
| | - Josef Mašek
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Milan Kuchař
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v.v.i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic; (H.P.); (M.K.)
| | - Andrea Vítečková Wünschová
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Jana Štikarová
- Department of Biochemistry, Institute of Hematology and Blood Transfusion, U nemocnice 2094/1, 128 20 Praha 2, Czech Republic; (J.Š.); (J.E.D.)
| | - Eliška Bartheldyová
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Pavel Kulich
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - František Hubatka
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Jan Kotouček
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Pavlína Turánek Knotigová
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Eva Vohlídalová
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Renata Héžová
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Eliška Mašková
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
| | - Stuart Macaulay
- Malvern Instruments Ltd., Enigma Business Park, Grove Lane, Malvern WR14 1XZ, UK;
| | - Jan Evangelista Dyr
- Department of Biochemistry, Institute of Hematology and Blood Transfusion, U nemocnice 2094/1, 128 20 Praha 2, Czech Republic; (J.Š.); (J.E.D.)
| | - Milan Raška
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 3, 775 15 Olomouc, Czech Republic
| | - Robert Mikulík
- The International Clinical Research Center ICRC and Neurology Department of St. Anne’s University Hospital in Brno, Pekařská 53, 656 91 Brno, Czech Republic;
| | - Petr Malý
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v.v.i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic; (H.P.); (M.K.)
- Correspondence: (P.M.); (J.T.); Tel.: +420-325-873-763 (P.M.); +420-732-813-577 (J.T.)
| | - Jaroslav Turánek
- Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; (J.M.); (A.V.W.); (E.B.); (P.K.); (F.H.); (J.K.); (P.T.K.); (E.V.); (R.H.); (E.M.)
- Correspondence: (P.M.); (J.T.); Tel.: +420-325-873-763 (P.M.); +420-732-813-577 (J.T.)
| |
Collapse
|
4
|
Clavaud M, Lema-Martinez C, Roggo Y, Bigalke M, Guillemain A, Hubert P, Ziemons E, Allmendinger A. Near-Infrared Spectroscopy to Determine Residual Moisture in Freeze-Dried Products: Model Generation by Statistical Design of Experiments. J Pharm Sci 2019; 109:719-729. [PMID: 31499067 DOI: 10.1016/j.xphs.2019.08.028] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Revised: 08/27/2019] [Accepted: 08/27/2019] [Indexed: 11/26/2022]
Abstract
Moisture content (MC) is a critical quality attribute of lyophilized biopharmaceuticals and can be determined by near-infrared (NIR) spectroscopy as nondestructive alternative to Karl-Fischer titration. In this study, we create NIR models to determine MC in mAb lyophilisates by use of statistical design of experiments (DoE) and multivariate data analysis. We varied the composition of the formulation as well as lyophilization parameters covering a large range of representative conditions, which is commonly referred to as "robustness testing" according to quality-by-design concepts. We applied principles of chemometrics with partial least squares and principal component analysis. The NIR model excluded samples with complete collapse and MC > 6%. The 2 main components in the principal component analysis were MC (91%) and protein:sugar ratio (6%). The third component amounted to only 3% and remained unspecified but may include variations in process parameters and cake structure. In contrast to traditional approaches for NIR model creation, the DoE-based model can be used to monitor MC during drug product development work including scale-up, and transfer without the need to update the NIR model if protein:sugar ratio and MC stays within the tested limits and cake structure remains macroscopically intact. The use of the DoE approach and multivariate data analysis ensures product consistency and improves understanding of the manufacturing process.
Collapse
Affiliation(s)
- Matthieu Clavaud
- Quality Control for Commercial Bulk Products, Analytical Science and Technology, F. Hoffmann-La Roche Ltd., Wurmisweg, CH-4303 Kaiseraugst, Switzerland; University of Liege, CIRM, Vibra-Santé Hub, Laboratory of Pharmaceutical Analytical Chemistry, Department of Pharmacy, Quartier Hôpital, Avenue Hippocrate 15, B36, B-4000 Liege, Belgium.
| | - Carmen Lema-Martinez
- Pharmaceutical Development & Supplies Biologics Europe, F. Hoffmann-La Roche Ltd., Grenzacherstrasse, CH-4070 Basel, Switzerland
| | - Yves Roggo
- 2 rue Arthur Rimbaud, 68510 Sierentz, France
| | - Michael Bigalke
- Pharmaceutical Development & Supplies Biologics Europe, F. Hoffmann-La Roche Ltd., Grenzacherstrasse, CH-4070 Basel, Switzerland
| | - Aurélie Guillemain
- Quality Control for Commercial Bulk Products, Analytical Science and Technology, F. Hoffmann-La Roche Ltd., Wurmisweg, CH-4303 Kaiseraugst, Switzerland
| | - Philippe Hubert
- University of Liege, CIRM, Vibra-Santé Hub, Laboratory of Pharmaceutical Analytical Chemistry, Department of Pharmacy, Quartier Hôpital, Avenue Hippocrate 15, B36, B-4000 Liege, Belgium
| | - Eric Ziemons
- University of Liege, CIRM, Vibra-Santé Hub, Laboratory of Pharmaceutical Analytical Chemistry, Department of Pharmacy, Quartier Hôpital, Avenue Hippocrate 15, B36, B-4000 Liege, Belgium
| | - Andrea Allmendinger
- Pharmaceutical Development & Supplies Biologics Europe, F. Hoffmann-La Roche Ltd., Grenzacherstrasse, CH-4070 Basel, Switzerland.
| |
Collapse
|